Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life

Background. Several drugs which are easy to administer in outpatient settings have been authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to prevent hospital admission and death, complementing COVID-19 vaccines. However, the evidence on the efficacy of COVID-19 antiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Cegolon, Luca, Pol, Riccardo, Simonetti, Omar, Larese Filon, Francesca, Luzzati, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221734/
https://www.ncbi.nlm.nih.gov/pubmed/37242504
http://dx.doi.org/10.3390/ph16050721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221734/
https://www.ncbi.nlm.nih.gov/pubmed/37242504
http://dx.doi.org/10.3390/ph16050721

Ejemplares similares